Intracellular cholesterol transporters and modulation of hepatic lipid metabolism: implications for diabetic dyslipidaemia and steatosis by Soffientini, Ugo et al.
Intracellular cholesterol transporters and modulation of hepatic lipid metabolism:
implications for diabetic dyslipidaemia and steatosis
Soffientini, Ugo; Caridis, Anna-Maria; Dolan, Sharron; Graham, Annette
Published in:







Link to publication in ResearchOnline
Citation for published version (Harvard):
Soffientini, U, Caridis, A-M, Dolan, S & Graham, A 2014, 'Intracellular cholesterol transporters and modulation of
hepatic lipid metabolism: implications for diabetic dyslipidaemia and steatosis', Biochimica et Biophysica Acta
(BBA), vol. 1842, no. 10, pp. 1372-1382. https://doi.org/10.1016/j.bbalip.2014.07.002
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please view our takedown policy at https://edshare.gcu.ac.uk/id/eprint/5179 for details
of how to contact us.




Intracellular cholesterol transporters and modulation of hepatic lipid 
metabolism: implications for diabetic dyslipidaemia and steatosis 
 
Ugo Soffientini ● Anna-Maria Caridis ● Sharron Dolan ●Annette Graham§ 
Diabetes Research Group, Institute for Applied Health Research and the Department of Life 
Sciences, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, 
United Kingdom 
 
§Corresponding author: Prof Annette Graham, Charles Oakley Laboratories, Department of 
Life Sciences, School of Health and Life Sciences, 70 Cowcaddens Road, Glasgow G4 0BA, 
UK 
T: +44(0) 141 331 3722 F: +44(0) 141 331 3208 E: Ann.Graham@gcu.ac.uk 
 
Word Count: 7158 
Abstract: 246 
























To examine hepatic expression of cholesterol-trafficking proteins, mitochondrial StarD1 and 
endosomal StarD3, and their relationship with dyslipidaemia and steatosis in Zucker (fa/fa) 
genetically obese rats, and to explore their functional role in lipid metabolism in rat McArdle 
RH-7777 hepatoma cells. 
Methods 
Expression of StarD1 and StarD3 in rat liver and hepatoma samples were determined by Q-
PCR and/or immunoblotting; lipid mass by colorimetric assays; radiolabelled precursors 
were utilised to measure lipid synthesis and secretion, and lipidation of exogenous 
apolipoprotein A-I. 
Results 
Hepatic expression of StarD3 protein was repressed by genetic obesity in (fa/fa) Zucker rats, 
compared with lean (Fa/?) controls, suggesting a link with storage or export of lipids from the 
liver.  Overexpression of StarD1 and StarD3, and knockdown of StarD3, in rat hepatoma 
cells, revealed differential effects on lipid metabolism.  Overexpression of StarD1 increased 
utilisation of exogenous (preformed) fatty acids for triacylglycerol synthesis and secretion, 
but impacted minimally on cholesterol homeostasis.  By contrast, overexpression of StarD3 
increased lipidation of exogenous apoA-I, and facilitated de novo biosynthetic pathways for 
neutral lipids, potentiating triacylglycerol accumulation but possibly offering protection 
against lipotoxicity.  Finally, StarD3 overexpression altered expression of genes which 
impact variously on hepatic insulin resistance, inducing Ppargcla, Cyp2e1, Nr1h4, G6pc and 
Irs1, and repressing expression of Scl2a1, Igfbp1, Casp3 and Serpine 1.   
Conclusions/Interpretation 
Targeting StarD3 may increase circulating levels of HDL and protect the liver against 
lipotoxicity; loss of hepatic expression of this protein, induced by genetic obesity, may 
contribute to the pathogenesis of dyslipidaemia and steatosis. 
 
Keywords Insulin resistance, lipid metabolism, high density lipoprotein, steatosis, 











ABCA1 ATP Binding Cassette transporter A1 
Actb  Beta-actin 
ApoA-I  Apolipoprotein A-I 
B2m  Beta-2 microglobulin 
Cyp2E1 Cytochrome P450 2E1 
FXR  Farnesoid X Receptor 
Gapdh  Glyceraldehyde-3-phosphate Dehydrogenase 
GLUT1 Glucose Transporter 1 
HDL  High Density Lipoprotein 
Hprt1  Hypoxanthine phosphoribosyltransferase 1 
Igfbp  Insulin Growth Factor Binding Protein 
Irs1  Insulin Receptor Substrate 1 
LdhA  Lactate Dehydrogenase A 
LDL  Low Density Lipoprotein 
MENTAL MLN64 N-terminal 
MLN64 Metastatic Liver Node 64; StarD3 
NAFLD Non-alcoholic Fatty Liver Disease 
NASH  Non-alcoholic Steatohepatitis 
PGC-1 Peroxisome Proliferator Activated Receptor Gamma Coactivator 1-alpha 
Rplp1  Ribosomal Protein, Large, P1 
Srebp  Sterol Regulatory Element Binding Protein 
StAR  Steroidogenic acute regulatory protein (StarD1) 
StarD  Steroidogenic acute regulatory protein (StAR)-related domain 















Hepatic insulin resistance triggers an atherogenic dyslipidaemia, characterised by high 
levels of triglyceride-rich very low density lipoproteins (VLDL) and their cholesteryl ester-rich 
remnant particles, low levels of high density lipoprotein (HDL), and small dense low density 
lipoproteins (LDL) [1-4].  Overproduction of large VLDL1 is driven by increased flux of non-
esterified fatty acids from adipose tissue, upregulation of sterol regulatory element binding 
protein-1c (SREBP-1c), chronic stimulation of de novo lipogenesis, and reduced fatty acid 
oxidation in the liver [1-4].  Circulating HDL levels are maintained by hepatic ABCA1 [5], 
insulin resistance causes loss of hepatic ABCA1 protein expression [5-9] and a strong 
reciprocal relationship exists between ABCA1 expression and hepatic VLDL output [10-13], 
integrating triglyceride and cholesterol lipoprotein metabolism.  Dysregulated hepatic lipid 
metabolism also contributes to non-alcoholic fatty liver disease (NAFLD), present in 70-80% 
of diabetic and obese patients [14], and a condition which ranges from simple steatosis (SS) 
to steatosis combined with necrosis and inflammation (non-alcoholic steatohepatitis; NASH) 
which can progress to hepatic fibrosis and cirrhosis [14-18].   Crucially, hepatic accumulation 
of free cholesterol exacerbates development of NASH and fibrosis, while correction of 
cholesterol overload reduces the severity of liver disease [16-18].  Since NASH confers a 
1.8-fold higher mortality, and itself increases risk of type 2 diabetes and cardiovascular 
disease [14,15], it is clear that effective treatments for diabetic dyslipidaemia and NAFLD are 
urgently needed.   
One approach could be to sustain, or improve, the efficiency of intracellular cholesterol 
transport within the liver, particularly when challenged by exposure to elevated levels of 
glucose, fatty acids and atherogenic lipoprotein remnants.  Non-vesicular trafficking of lipids 
is mediated, in part, by the steroidogenic acute regulatory protein (StAR)-related lipid 
transfer (START) domain family.   The START domain is a ~210 amino acid helix-grip 
fold, found in 15 distinct mammalian proteins (STARD1-D15), providing an adaptable 
hydrophobic lipid binding or sensing site for sterols, bile acids, phospholipids, ceramides and 
small drug molecules [19-21].  The prototypic member of this family, steroidogenic acute 
regulatory protein (StAR; StarD1) is a mitochondrial cholesterol trafficking protein primarily 
involved in steroidogenesis [19-21].  In the liver, StAR supplies cholesterol to the cytochrome 
P450 enzyme, CYP27A1, located on the inner mitochondrial membrane, facilitating 
metabolism of this sterol via the alternative bile acid pathway [22-25].  The other member of 
the StarD1 subfamily, StarD3 (Metastatic Lymph Node 64), is a 54 kDa endosomal 
cholesterol trafficking protein, variously reported to facilitate trafficking of cholesterol to the 
endoplasmic reticulum, mitochondria and the plasma membrane [26-29].  Certainly, 
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overexpression of either StarD1 or StarD3 enhances bile acid synthesis via CYP27A1 in 
primary rat hepatocytes [23].   
Importantly, our previous work demonstrated that expression of both StarD1 and StarD3 are 
regulated by lipid-responsive transcription factors [30], and that overexpression of StarD1, or 
StarD3, in macrophages enhances expression of ABCA1, and cholesterol efflux to acceptor 
(apo)lipoproteins [31, 32].  This led to dual hypotheses: that loss of these proteins may be 
implicated in diabetic dyslipidaemia or steatosis, and that targeting these proteins may help 
to resolve the problems of low HDL and/or overproduction of VLDL by diabetic liver. Thus, 
we examined expression of StarD1 and StarD3, members of the StarD1 subfamily of lipid 
trafficking proteins, and their relationship with dyslipidaemia and hepatic steatosis, in the 
Zucker (fa/fa) rodent model of genetic obesity [33], and explored their functional role in lipid 
synthesis and secretion by genetically manipulating expression of these proteins in rat 
McArdle RH7777 hepatoma cells. 
Methods 
Materials 
Apolipoprotein A-I was purchased from Athens Research and Technology (Georgia, USA). 
All other materials were from UK companies, or UK suppliers for the companies indicated.  
Radiochemicals were purchased from Perkin Elmer, Tri-Fast from PeqLab and cDNA 
synthesis kits from Bioline.  Rabbit polyclonal antibodies to Cyp27A1, Gapdh and StarD3 
were purchased from AbCAM, and to StarD1 from Santa Cruz.  Sodium pentobarbital was 
supplied by J.M. Loveridge plc, (Southampton), tissue culture reagents from Lonza, and 
sterile tissue culture plastics from Greiner.  Silencing RNA was purchased from Integrated 
DNA Technologies, and StarD1 and StarD3 rodent clones (pCMV) from Origene.com via 
Cambridge Biosciences. Complete™ protease inhibitor cocktail was purchased from Roche, 
primers and probes (FAM/TAMRA) from EuroGenTech, and Rat Fatty Liver RT2-PCR arrays 
from SABiosciences (Qiagen).  Chemicals, t.l.c.plates and solvents were purchased from 
Sigma Aldrich.   
Experimental animals 
Heterozygous Zucker rats (Fa/fa) were purchased from Harlan Laboratories (Bicester, UK) 
and a breeding colony established.  Rats were maintained in group (n=3) cages on sawdust 
bedding, on a 14h-light/10h-dark cycle with standard chow and water provided ad libitum.  
Male lean (Fa/?; n=10) and obese (fa/fa; n=6), and female lean (n=5) and obese (n=4) rats 
were terminally anaesthetized at four months, using pentobarbital sodium (100mg kg-1, I.P); 
blood was collected by cardiac puncture, and plasma levels of glucose and lipids 
determined, as described [33].  Principles of laboratory animal care (NIHA publication no. 
85-23, revised 1985 (http://grants1.nih.gov/grants/olaw/references/phspol.htm) were 
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followed. The study was approved by the institution’s Animal Ethics and Welfare Committee, 
and procedures performed according to the UK Animals (Scientific Procedures) Act, 1986. 
Preparation of tissue samples Samples (100mg) of liver were suspended in 
Dulbecco’s phosphate buffered saline (1ml), using a Beadbeater (Thistle Scientific, UK), and 
a Bligh and Dyer (1959) lipid extraction performed [34].  Lipid extracts were dried under N2, 
and lipid mass measured, as described [30-32].  Total RNA from liver (60mg) was isolated 
after homogenisation in 500l of TriFast™, genomic DNA removed by treatment with 
DNase, and cDNA prepared by reverse transcription; negative controls, omitting reverse 
transcriptase enzyme, were included for each sample.  Hepatic protein lysates were 
prepared in RIPA buffer plus Complete™protease inhibitor cocktail.   
Cell culture and experiments  Rat McArdle RH7777 (CRL-1601; ATCC) cells, derived 
from female Rattus norvegicus (Morris hepatoma 7777) were maintained  in DMEM 
(Dulbecco’s Modified Eagle Medium) containing foetal bovine serum (10% v/v), 
penicillin/streptomycin (50U/ml, 50μg/ml respectively), sodium bicarbonate (NaCO3 0.06% 
w/v), HEPES buffer (10mM) and L-glutamine (2mM), at 37°C in a humidified atmosphere of 
95% air and 5% CO2.   McArdle RH7777 cells were selected for this study, as they retain the 
ability to secrete VLDL1 and VLDL2 particles [48], containing both apoB48 and apoB100 [49], 
49], which can be stimulated in a dose-dependent manner by exogenous non-esterified fatty 
acids [50].   Successful transfection studies, manipulating DGAT-1 and ACAT-1/2 activity, 
have been performed in this cell line, resulting in altered secretion of apoB lipoproteins [51].   
However, it should be noted that McArdle hepatoma cells differ somewhat in their nutrient 
partitioning, compared with primary rat hepatocytes [52].  Hansson et al (2004) 
demonstrated that hepatoma cells had a higher rate of fatty acid uptake (2-fold), and a lower 
rate of fatty acid oxidation (2-fold), compared with primary hepatocytes.  Further, McA-
RH7777 cells metabolised glucose to lipids or into oxidation, rather than synthesizing 
glycogen, unlike primary hepatocytes [52].  It has also been demonstrated that McA-RH777 
cells exhibit impaired utilisation of triglycerides derived from recycling of phospholipids, 
resulting in VLDL particles with a slightly different triglyceride composition than those 
produced by primary hepatocytes [53].   
Transfection of McArdle cells with 2g of empty vector (EV; pCMV.Neo) or the same vector 
encoding full length rodent StarD1 or StarD3 was achieved using Amaxa Nucleofector-II (Kit 
V, protocol T-028).  Stable populations were selected using G418 (400g ml-1).  Transient 
delivery (48h) of silencing RNA (100nM) was delivered using the same protocol.   
Lipidation of apoA-I (10g ml-1; 24h) was assessed in cells labelled with 0.5Ci ml-1 
[3H]cholesterol, as described [29-31].  For lipid synthesis and secretion experiments, cells 
were cultured in serum-free DMEM in presence of [1-2 14C]acetate (1.5µCi/ml; 0.5mM), [1-
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14C]oleate (1µCi/ml; 0.7mM complexed 1:1 with BSA) or [2-3H]glycerol (1.18µCi/ml; 0.25mM) 
for 2h, in the presence or absence of 0.35mM oleate/BSA (1:1) complex; concentrations of 
acetate (0.5mM) and glycerol (0.25mM) remained the same under all conditions tested.   
Lipid Analyses  Samples of media were extracted according to Bligh and Dyer (1959), 
and cellular lipids using hexane:isopropanol (3:2, v/v), as detailed [30-32], and  extracts 
dried under N2 before resuspension in isopropanol containing rat liver lipids, and separation 
by t.l.c. using petroleum ether: diethyl ether: glacial acetic acid (90:30:1 by vol.) as the 
mobile phase.  Lipids were identified by comparison with authentic standards, and dpm 
determined by scintillation counting (Hidex 300SL).    
Gene and protein analyses Levels of mRNA encoding StarD1 and StarD3 were measured 
relative to Gapdh, as described [29-31]; specific sequences for primers and fluorescent 
probes (FAM/TAMRA) StarD3 sense  (5’-TGCCCAGGCTGCTGTTG-3’) 
antisense (5’-GAGAGTAGAACTGGCCCTCAGACA-3’), probe (5’-CCGTGGACCCC 
TTCTATTCTCCGGT-3’); StarD1 sense  (5’-AACTGGAAGCAACACTCTACAGTG-3’), 
antisense       (5’-AGGCCTTTTGCATAGCTTCCT-3’) probe   (5’-CAGGAGCTGTCCT 
ACATCCAGCAAGGA-3’); GAPDH sense        (5’-CAACTACATGGTCTACATGTTCCA 
GTATG-3’), antisense                  (5’-CTTCCCATTCTCAGCCTTGACT-3’), probe (5’-CT 
CCCACGGCAAGTTCAACGGCA-3’).   
Gene expression of Dgat1, Dgat2 and Nrih3, relative to Gapdh, were measured using 
commercial primers and Sybr Green (Maxima SYBR Green QPCR Master Mix), using the 
following primer sequences: Dgat1  sense (5’-CGGATAGCTTACAGTGTTCTG-3’), 
antisense (5’-CATCATACTCCATCATCTTCCTCA-3’); Dgat2 sense (5’-
GCCAGGTGACAGAGAAGATG-3’), antisense (5’-GCAGCGAGAACAAGAATAAAG-3’); 
Nr1h3 sense (5’-GCTCCTCTTCTTGACGCTTC-3’), antisense (5’-
AGTGTCGCCTTCGCAAA-3’) and Gapdh, sense (5'-GTAACCAGGCGTCCGATAC-3') 
and antisense (5'-TCTCTGCTCCTCCCTGTTC-3'). 
Results are expressed as ratio to Gapdh, using the 2-Ct comparison method (Applied 
Biosystems).  Hepatic protein lysates were separated using 10% (w/v) SDS PAGE gels, 
transferred to nitrocellulose membranes, and probed using rabbit polyclonal antibodies to 
Cyp27A1 (1:1000), StarD1 (1:1000), StarD3 (1:4000) and Gapdh (1:1000) as previously [30-
32], except that fluorescently-labelled secondary antibodies (Licor) were employed and 
bands quantified using a Licor Odyssey FC and Image Studio software.    
Statistical analysis All values indicate mean±SEM; n denotes numbers of independent 
determinations.  Significant (p<0.05) differences were determined using Student’s t-test, or 




Hepatic expression of StarD1 and StarD3 in obese, hyperlipidaemic and steatotic fa/fa rats 
Expression of StarD1 and StarD3 were examined in four month old obese Zucker (fa/fa) rats, 
compared with lean (Fa/?) rats.  At this age, fa/fa rats are normoglycaemic, but exhibit 
weight gain and hyperinsulinaemia [33], hyperlipidaemia and/or hepatic lipid accumulation 
(Figure 1a) compared with lean controls.  Obese (fa/fa) male rats (583±9.0g; n=6) weighed 
significantly (p<0.001) more than lean controls of the same gender (384±11g; n=10); fa/fa 
female rodents also weighed significantly (p<0.001) more than lean controls (228±11.5g; 
n=5. versus 494±9.4g; n=4).  Blood glucose levels were 8.3±0.3mmol l-1 and 7.7±0.3 mmol l-
1 in obese and lean male rats, and 6.7±0.4 mmol l-1 and 7.4±0.4 mmol l-1 in obese and lean 
female rats respectively.  Serum cholesterol, triacylglycerol and phospholipids were elevated 
in obese male and female rats compared to lean rats of the same gender (Fig 1a).  Obese 
male Zucker rats accumulated greater quantities of hepatic triacylglycerol and phospholipids 
than obese female rats, while obese female rats were characterized by a more profound 
hyperlipidaemia (Fig 1a), providing an interesting model in which to investigate gene 
expression of cholesterol-binding StarD1 subfamily of lipid trafficking proteins.   
Levels of mRNA encoding StarD1 and StarD3, relative to Gapdh, are shown in Figure 1b.  
No significant changes in expression of StarD1 were noted in hepatic tissues (n=4) from lean 
and obese rats, of either gender.   By contrast, levels of StarD3 (48%; p<0.01; n=4) mRNA 
decreased in hepatic tissues from obese, compared to lean male rats; a similar trend, albeit 
non-significant, was noted in hepatic tissues from obese compared with lean female rats.  
While levels of StarD1 protein were low and difficult to detect by Western blotting, as 
previously noted [25], expression of StarD3 protein was markedly regulated, and 
substantively higher (2.27-fold; p<0.001; n=4 and 11.45-fold; p<0.01; n=4) in female lean 
and obese rats, compared with male lean and obese rats, respectively (Figure 1c).   
Equally, the presence of obesity induced marked decreases in hepatic levels of StarD3 
protein in male (11.65-fold; p<0.01) and female (2.31-fold; p<0.001) rats, resulting in 
equivalent levels of StarD3 protein in lean male and obese female rats.  
These data implied a relationship between hepatic levels of StarD protein and the ability of 
the liver to store or export lipids.  This possible causal modality was explored by stably 
overexpressing rodent StarD1 (10-fold; p<0.05) and StarD3 (1.32-fold; p<0.05) in rat 
McArdle (McA-RH7777) hepatoma cells (Figures 2b and 2d) which retain expression of 
CYP27A1 (Figure 2a).  Transient knockdown (4-fold; p<0.05) of StarD3 was achieved using 
SiRNA (100nM; 48h), compared with a scrambled SiRNA control.  The efflux of 
[3H]cholesterol to exogenous  apoA-I (10g ml-1; 24h), one measure of ABCA1 activity,  is 
shown in Figure 2b and 2d.  Overexpression of StarD3, but not StarD1, significantly 
increased the lipidation of apoA-I by 1.66-fold (p<0.01) (Figure 2e), while knockdown of 
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StarD3 tended to reduce cholesterol efflux slightly (NS) (Figure 2f).  This suggested that 
increasing hepatic levels of StarD3 could enhance circulating levels of HDL, although this 
finding requires validation in vivo .   
Cholesterol synthesis, esterification and secretion into the medium were also studied in 
these cell lines, under basal conditions, and following treatment with non-esterified fatty acid 
to stimulate synthesis and secretion of neutral lipids (Figure 3). The incorporation (2h) of 
[14C]acetate into synthesized and secreted cholesterol, and cholesteryl ester are shown in 
Figures 3a to 3d.  No changes in either synthesized or secreted [14C]cholesterol were noted 
in cells overexpressing StarD1 or StarD3, but StarD3 overexpression significantly increased 
incorporation of [14C]acetate into hepatic cholesteryl esters under basal conditions (1.8-fold; 
p<0.05) and following incubation with 0.35mM oleate (1.3-fold; p<0.01) (Figure 3c).  The 
total cholesterol mass of EV (0.49 ± 0.06 mg mg-1 protein), StarD1 (0.44 ±0.07 mg mg-1 
protein) and StarD3 (0.43 ± 0.07 mg mg-1 protein) cell lines did not change significantly, 
either in the presence or absence of 0.35mM oleate.  The incorporation of 0.7mM [14C]oleate 
into the cholesteryl ester pool within these hepatocytes did not change, although decreased 
(45%; p<0.01) secretion of cholesteryl [14C]oleate was noted (Figure 3f).   
The impact of StarD1 and StarD3 overexpression on synthesis and secretion of 
triacylglycerol, the major neutral lipid generated in hepatic cells, is shown in Figure 4.  
Incorporation of [3H]glycerol into hepatic triacylglycerol (2h) (Figure 4a) was significantly 
increased by overexpression of StarD1 (2.26-fold; p<0.05) and StarD3 (2.04-fold; p<0.05) in 
McArdle cells under basal conditions.  These effects were essentially lost when the cells 
were challenged by the presence of 0.35mM oleate, which significantly increased (8-fold; 
p<0.001) biosynthesis of triacylglycerol. The secretion of triacylglycerol (2h) labelled with 
[3H]glycerol was also stimulated by the addition of 0.35mM oleate (1.9-fold; p<0.05), but was 
not changed in cells overexpressing StarD1 or StarD3 (Figure 4). Increased [14C]acetate 
incorporation (2h) into the cellular triacylglycerol pool was noted in StarD3 (1.8-fold; p<0.05) 
overexpressing cells; again, this effect was abrogated in the presence of 0.35mM oleate 
(Figure 4c).  No changes in secretion of de novo synthesized [14C]triacylglycerol were noted 
(Figure 4d).   The triacylglycerol mass tended to increase in the presence of 0.35mM oleate 
(2h) in EV (0.89 ± 0.06 mg mg-1 protein versus 0.35mM oleate 1.07 ± 0.15 mg mg-1 protein; 
n=3; NS), and this increase was potentiated by overexpression of StarD1 (0.71 ±0.03 mg 
mg-1 protein versus 0.35 mM oleate 1.52 ± 0.20 mg mg-1 protein; n=3; NS) and StarD3 (0.69 
±0.04 mg mg-1 protein versus 0.35mM oleate 1.18± 0.09 mg mg-1 protein; n=3; p<0.05).  
Most notably, when the McArdle cell lines were incubated with 0.7mM [14C]oleate (2h), 
StarD1 but not StarD3, significantly enhanced incorporation of this fatty acid into synthesized 
(1.43-fold; p<0.05) and secreted (1.6-fold; p<0.05) triacylglycerol; these trends were also 
observed in the presence of additional unlabelled oleate (Figure 4e). Taken together, these 
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data indicate differential effects of StarD1 and StarD3 overexpression on hepatic 
triacylglycerol synthesis and/or secretion.    
Accordingly, we measured expression of the genes encoding DGAT-1 and DGAT-2 in 
samples of rodent liver (Figures 5a and 5b) and in StarD1 and StarD3 overexpressing cells, 
compared with empty vector controls (Figures 5c and 5d).   While no significant differences 
in hepatic Dgat1 expression were noted in male or female, lean or obese rats, the 
expression of Dgat2 was significantly higher in obese female rats, when compared with lean 
female controls (1.86-fold; p<0.01), and with obese male rats (2.3-fold; p<0.01) (Figure 2b).   
Overexpression of StarD1 in McA-RH7777 cells induced a 2.3-fold change in expression of 
Dgat1, and an almost 3-fold increase in Dgat2 expression, compared with EV control.  By 
contrast, Dgat1 levels were 40% lower in StarD3 overexpressing cells, while Dgat2 levels 
were elevated by 2.2-fold compared with the EV control.   
Hepatic expression of the gene encoding LXR(Nr1h3) was also significantly higher in lean 
female rats, compared with lean male rats (1.5-fold; p<0.05), obese male rats (2.2-fold; 
p<0.01) and obese female rats (2.5-fold; p<0.01) (Figure 5e).  Levels of Nr1h3 were low in 
McA-RH7777 EV controls; a modest repression was seen in StarD1 overexpressing cells 
(23%), and in StarD3 overexpressing cells (58%).  However, we note this latter repression 
was not seen when this gene was investigated in StarD3 overexpressing cells using 
commercial Q-PCR arrays (Figure 7b), suggesting that the level of this transcription factor 
may fluctuate, or that the low level of expression of this gene may preclude accurate 
quantitation.    
The effect of StarD3 knockdown (Figure 2a) on hepatic lipid synthesis and secretion is 
shown in Figure 6.  Incorporation of [14C]acetate into cellular cholesterol and cholesteryl 
ester decreased by 59% (p<0.05) and 81% (p<0.01) (Figure 6a); a decrease (71%; p<0.01) 
in secretion of de novo synthesized cholesteryl ester was also noted (Figure 6b). The 
incorporation of [3H]glycerol and [14C]oleate into synthesized and secreted triacylglycerol 
were not significantly affected by StarD3 knockdown, but incorporation of [14C]acetate into 
the cellular triacylglycerol pool declined significantly (58.5%; p<0.05).  Thus, the knockdown 
of StarD3 exerted opposite effects to StarD3 overexpression on incorporation of [14C]acetate 
into cellular triacylglycerol, and also reduced flux of this isotope into de novo synthesized 
cholesterol and cholesteryl ester pools.   
The impact of StarD3 overexpression on expression of genes involved in insulin signalling, 
cholesterol metabolism and transport, carbohydrate and lipid metabolism, and inflammation 
and apoptosis, are shown in Figure 7.    Modest, but statistically significant increases in 
expression of Abca1 (1.5-fold; p<0.001) and Dgat2 (1.4-fold; p<0.001) were seen in StarD3 
overexpressing hepatocytes, compared with EV, supporting the data in Figures 2, 4 and 5.  
However, gene expression changes of ≥2-fold were considered biologically significant.  Five 
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housekeeping genes were monitored between test StarD3/EV control hepatocytes, yielding 
the following fold-change values (n=3) forActb (0.97±0.04), B2m (0.96±0.04), Hprt1 (1.33± 
0.05),Ldha (0.91 ± 0.01) and Rplp1(0.89±0.04).  Increases in expression of genes encoding 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α; 8.6-fold; 
p<0.001), glucose 6-phosphatase (5.9-fold; p<0.001), cytochrome P450 2E1 (CYP2E1; 2.8-
fold; p<0.001), insulin receptor substrate 1 (2.6-fold; p<0.001) and the bile acid farnesoid X 
receptor (2.4-fold; p<0.001) were noted in StarD3 overexpressing hepatocytes.  By contrast, 
StarD3 overexpression was associated with down-regulation of serpine 1 (3.8-fold; p<0.001), 
glucose transporter 1 (GLUT1; 2.8-fold; p<0.01), insulin growth factor binding protein 1 (2.1-
fold; p<0.001) and caspase 3 (2.1-fold; p<0.001).  Despite one previous report [35], 
expression of genes encoding proteins mediating inflammatory or apoptotic responses did 
not increase in StarD3 overexpressing hepatocytes, presumably reflecting the physiological 
levels of StarD3 utilised in this study. 
Discussion 
The present study demonstrates hepatic expression of StarD3 protein to be repressed by 
genetic obesity in both male and female rats.  Substantively higher levels of StarD3 protein 
were also noted in female, compared with male rats, raising the possibility that StarD3 might 
facilitate lipid export, rather than retention in the liver.   Alternatively, it was possible that lack 
of StarD3 might promote lipid accumulation within the liver and/or impair export in obese 
male rats.  Hepatic levels of StarD1, the other member of this subfamily, were detectable by 
Q-PCR, but not Western blotting, as previously reported [24], and also tended to decline 
somewhat in genetic obesity.  Overexpression of rodent StarD1 and StarD3, and knockdown 
of StarD3, in McArdle hepatoma cells, allowed evaluation of the causal relationship between 
these proteins, and lipid synthesis and secretion by the liver.  In interpreting these data, it is 
important to recognise that differences exist between McA-RH7777 cells and primary rat 
hepatocytes: hepatoma cells preferentially utilise fatty acids rather than glucose, which may 
reflect the demand for lipid substrates to sustain membrane biogenesis in proliferating cells 
[48]. 
Dissection of cholesterol homeostasis in StarD1 overexpressing cells did not yield any 
significant differences, when compared to the EV; by contrast, overexpression of StarD3 
increased the flux of [14C]acetate into the cholesteryl ester pool,  and stimulated cholesterol 
efflux to exogenous apoA-I.   The latter finding agrees well with previous studies 
demonstrating increased expression of ABCA1 and efflux of cholesterol to apoA-I in human 
macrophages [32], and with the suggestion that STARD3 can access a pool of cholesterol in 
‘early’ late endosomes, readily amenable to recycling to the plasma membrane [27].   
However, the FFAT motif within an acidic tract in StarD3 interacts with ER-anchored VAP 
proteins to increase the formation of inter-organelle membrane contact sites between late 
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endosomes and the ER [26], and StarD3 can also deliver cholesterol to mitochondria [23, 
28, 29, 36, 37].  Indeed, enhanced flux of [14C]acetate into the cholesteryl ester pool 
suggests increased total cholesterol biosynthesis and, therefore, efficient transport of 
cholesterol away from the ER.  Knockdown of StarD3 decreased de novo synthesis of 
hepatic cholesterol and cholesteryl esters, which implies accumulation of cholesterol at the 
ER, and may reflect loss of cholesterol delivery from endosomes to the plasma membrane or 
mitochondria.  This conclusion is supported by the modest increases in cholesteryl ester 
mass noted in mice in which the START domain of StarD3 was deleted [38]. 
Analysis of the synthesis of triacylglycerol from differing precursors revealed differential 
effects of StarD1 and StarD3: StarD1 overexpression tended to preferentially facilitate the 
incorporation of exogenously derived oleate into the triacylglycerol pool, while StarD3 
overexpression increased formation of de novo synthesized triacylglycerol.  Knockdown of 
StarD3 blocked incorporation of [14C]acetate into the hepatic triacylglycerol pool, without 
reducing incorporation of [3H]glycerol.   Basal levels of triacylglycerol synthesis were not, 
therefore, altered by StarD3 knockdown; it is possible that enhanced uptake of glucose via 
GLUT1 (Figure 6) could have diluted the pool of radiolabelled acetyl CoA available for 
incorporation into lipid pools.   
Diacylglycerol acyl transferase-2 (DGAT-2) utilises glycerol-3-phosphate and de novo 
synthesized fatty acids as substrates to form de novo synthesized triacyglycerol [39].  A 
small amount of this triacylglycerol is sequestered for secretion with apoB, and some is 
stored as cytosolic lipid droplets; however, the majority undergoes hydrolysis to yield partial 
glycerides which can then be resterified by DGAT-1, which utilises exogenously derived fatty 
acids.  The activity of DGAT1 on the luminal side of the endoplasmic reticulum membrane 
generates triacylglycerol used to lipidate nascent VLDL, prior to secretion [39].  Invoking this 
paradigm, it is possible that overexpression of StarD3 may preferentially promote the activity 
of DGAT-2, while StarD1 selectively enhances the activity of DGAT-1.    
Certainly, gene expression levels of Dgat2 appear to be with linked with protein levels of 
StarD3: hepatic levels of StarD3 are highest in lean female rats which express Dgat2 at 
higher levels than male lean and obese rats.  Protein levels of StarD3 decline in obese 
female rats, and this is mirrored by a decline in Dgat2 expression, while overexpression of 
StarD3 enhances the expression of Dgat2 while repressing expression of Dgat1.   By 
contrast, overexpression of StarD1 appears to enhance the expression of both Dgat1 and 
Dgat2, in agreement with previous findings indicating that both pathways are required to 
potentiate increased synthesis of triacylglycerol from preformed oleate [39] (Figures 4a and 
4e).   
At present, it is only possible to speculate as to the mechanisms by which these outcomes 
are achieved.  Changes in endoplasmic reticulum lipid composition, implied by data in 
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Figures 3 and 5, suggest activation of SREBPs which induce the expression of lipogenic 
enzymes.   Alternatively, enhanced transfer of cholesterol to mitochondria can enhance the 
generation of 27-hydroxycholesterol, activating Liver X receptors which stimulate expression 
of ABCA1, but also Srebp-1c, triggering lipogenic responses [31].   It is evident that lean 
female rats express higher hepatic levels of the gene encoding LXR than lean and obese 
male animals, and that LXR expression also declines with obesity in female rats (Figure 
5e). 
Certainly, StarD3 overexpression induces marked changes in gene expression in McArdle 
hepatoma cells, which may variously influence insulin resistance in the liver.  For example, 
induction of PGC1 [40], insulin receptor substrate 1 [41] and the farnesoid X receptor [42] 
have been associated with improved mitochondrial function, metabolic responses and/or 
sensitisation of the liver to insulin.  However, increased expression of glucose 6-
phosphatase, an established target of the transcriptional coactivator function of PGC-1, 
suggests StarD3 overexpression could exacerbate glycaemia in the fasting state [43]; 
moreover, induction of CYP2E1 is thought to enhance oxidative stress, another pathogenic 
trigger for onset of fatty liver disease [44].   Perhaps most intriguingly, StarD3 
overexpression markedly repressed the expression of serpine 1 (plasminogen activator 
inhibitor 1; PAI1), elevation of which was recently identified as a link between obesity, 
diabetes and cardiovascular disease [45].   
In summary, the mitochondrial and endosomal cholesterol-trafficking proteins, StarD1 and 
StarD3, appear to exert differing effects on hepatic lipid metabolism in McArdle hepatoma 
cells.  Mitochondrial StarD1 increases the utilisation of exogenous (preformed) fatty acids for 
triacylglycerol synthesis and secretion, but impacts minimally on cholesterol homeostasis. By 
contrast, endosomal cholesterol-trafficking protein, StarD3, appears to impact predominantly 
on cholesterol efflux to apoA-I, rather than the secretory pathway, and facilitates de novo 
biosynthesis of neutral lipids.  The former suggests one way of improving circulating levels of 
HDL, while in the latter context, it should be noted that it is not the accumulation of 
triacylglycerol per se that is damaging to the liver [46], but rather build-up of biologically 
active metabolites such as long-chain acyl CoAs, diacylglycerols and ceramides, which can 
impair insulin signalling and promote inflammatory responses [39].  Indeed, it has been 
suggested that triacylglycerol accumulation protects against fatty acid-induced lipotoxicity 
[47]; no evidence for increased inflammation or apoptosis was noted in StarD3 
overexpressing cells.  However, the link between StarD3 and DGAT-2 may potentiate the 
triglyceridaemia associated with Type 2 diabetes.  Further, since StarD3 overexpression also 
induced expression of a number of genes which impact variously on hepatic insulin 
resistance, further studies on the role of this cholesterol transport protein in diabetic murine 
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models are clearly warranted.  Thus, targeting StarD3 may increase circulating levels of HDL 
and protect the liver against lipotoxicity, while loss of expression of this protein may be part 
of the pathogenesis associated with hepatic steatosis. 
 
Acknowledgements  The authors would like to thank the excellent technical team in 
the Department of Life Sciences, GCU. 
Funding The authors are indebted to GCU for studentships supporting US and AMC, 
and to Diabetes UK for a small grant (11/0004333). 
Duality of interest The authors declare that there is no duality of interest associated with 
this manuscript. 
Contribution statement All authors participated in the design, or analysis, and 
interpretation of the data, contributed to the preparation of the manuscript, and gave their 
final approval of the version to be published. 
 
References 
1. Taskinen M R (2003) Diabetic dyslipidaemia: from basic research to clinical practice 
Diabetologia 46: 733-749 
2. Hiukka A, Fruchart J, Leinonen E, Hilden H, Fruchart J, Taskinen M (2005) 
Alterations of lipids and apolipoprotein CIII in VLDL subspecies in type 2 diabetes 
Diabetologia 48: 1207-1215 
3. Adiels M, Taskinen M-F, Packard C, Caslake M J, Soro-Paavonen A, Westerbacka J, 
Vehkavaara S, Hakkinen A, Olofsson S-O, Yki-Jarvinen H, Boren J (2006) 
Overproduction of large VLDL particles is drive by increased liver fat content in man 
Diabetologia 49: 755-765 
4. Elam M B, Wilcox H G, Cagen L M, Deng X, Raghow R, Kumar P, Heimberg M, 
Russell, J C (2001) Increased hepatic VLDL secretion, lipogenesis and SREBP-1 
expressioin in the corpulent JCR:LA-cp rat  J Lipid Res 42: 2039-2048 
5. Buechler C, Bauer S (2011) ATP binding cassette transporter A1 (ABCA1) 
associated proteins: potential drug targets in the metabolic syndrome and 
atherosclerotic disease?  Curr Pharma Biotechnol 13: 319 
6. Brunham L R, Kruit J K, Vechere B, Hayden M R (2008) Cholesterol in islet 
dysfunction and type 2 diabetes  J Clin Invest 118: 403-408 
7. Ehlers M B, Larson S M, Rasmussen H E, Park Y K, Lee J T (2011) High-density 
lipoprotein metabolism in human (B)100 transgenic/brown adipose tissue deficiency 




8. Nonomura K, Arai Y, Mitani H, Abe-Dohmae S, Yokoyama S (2011) Insulin down-
regulates specific activity of ATP-binding cassette transporter A1 for high density 
lipoprotein biogenesis through its specific phosphorylation Atherosclerosis 216: 334-
341 
9. Uehara Y, Engel T, Li Z, Goepfert C, Rust S, Zhou X, Langer C, Schachtrup C, 
Wiekowski J, Lorkowski S, Assmann G (2002) Polyunsaturated fatty acids and 
acetoacetate downregulate the expression of ATP binding cassette transporter A1 
Diabetes 51: 2922-2928 
10. Clee S M, Kastelein J J, Marcil M, Roomp K, Zwarts K Y, Collins J A, Roelants R, 
Tamasawa N, Stulc T, Suda T, Ceska R, Boucher B, Rondeau C, DeSouich C, 
Brooks-Wilson A, Molhuizen H O, Frohlich J, Genest J Jr, Hayden M R (2000) Age 
and residual cholesterol efflux affect HDL cholesterol levels and coronary artery 
disease in ABCA1 heterozygotes J Clin Invest 106: 1263-1270 
11. Chung S, Gebre A K, Seo J, Shelness G S, Parks J S (2010) A novel role for 
ABCA1-generated large pre-beta migrating nascent HDL in the regulation of hepatic 
VLDL triglyceride secretion  J Lipid Res 51: 729-742 
12. Chung S, Timmins J M, Duong M, Degirolamo C, Sawyer R S, Sawyer J K, Singaraja 
R R, Hayden M R, Maeda N, Rudel L L, Shelness G S, Parks J S (2010) Targeted 
deletion of hepatocytes ABCA1 leads to very low density lipoprotein overproduction 
and low density lipoprotein hypercatabolism  J BiolChem 285:12197-12209 
13. Liu M, Chung S, Shelness G S, Parks J S (2012) Hepatic ABCA1 and VLDL 
triglyceride production  BiochimBiophysActa 1821: 770-777 
14. Cusi K (2012) Role of obesity and lipotoxicity in the development of non-alcoholic 
steatohepatitis: pathophysiology and clinical implications Gastroenterol 142:e716 
15. Farrell G C, van Rooyen D, Gan L, Chitturi S (2012) NASH is an inflammatory 
disorder: pathogenic, prognostic and therapeutic implications  Gut Liver 6: 149-171 
16. Musso G, Gambino R,  Cassader M (2013) Cholesterol metabolism and the 
pathogenesis of non-alcoholic steatohepatitis Prog Lipid Res 52: 175-191 
17. Savard C, Tartaglione E V, Kuver R, Haigh W G, Farrell G C, Subramanian S, Chait 
A, Yeh M M, Quinn L S, Ioannou G N (2013) Synergistic interaction of dietary 
cholesterol and dietary fat in inducing experimental steatohepatitisHepatology 57: 81-
92 
18. Tomita K, Teratani T, Suzuki T, Shimizu M, Sato H, Narimatsu K, Okada, Y, Kurihara 
C, Irie R, Yokoyama H, Shimamura K, Usui S, Ebinuma H, Saito H, Watanabe C, 
Komoto S, Kawaguchi A, Nagao S, Sugiyama K, Hokari R, Kanai T, Miura S, Hibi T 
(2014) Free cholesterol accumulation in hepatic stellate cells: mechanism of liver 
fibrosis aggravation in non-alcoholic steatohepatitis in mice  Hepatology 59: 154-160 
16 
 
19. Soccio R E, Breslow J L (2003) StAR-related lipid transfer (START) proteins: 
mediators of intracellular lipid metabolism  J Biol Chem 278: 22183-22186 
20. Alpy F, Tomasetto C (2005) Gives lipids a START: the StAR-related lipid transfer 
(START) domain in mammals  J Cell Sci 188: 2791-2801 
21. Clark B J (2011) The mammalian START domain protein family in health and disease  
J Endocrinol 212: 257-275 
22. Pandak W M, Ren S, Marques D, Hall E, Redford K, Mallonee D, Bohdan P, Heuman 
D, Gil G, Hylemon P (2002) Transport of cholesterol into mitochondria is rate-limiting 
for bile acid synthesis via the alternative pathway in primary rat hepatocytes  J 
Biolchem 277: 48158-48164 
23. Ren S, Hylemon P, Marques D, Hall E, Redford K, Gil G, Pandak W M (2004) Effect 
of increasing the expression of cholesterol transporters (StAR, MLN64, and SCP-2) 
on bile acid synthesis  J Lipid Res 45: 2123-2131 
24. Ren S, Hylemon P B, Marques D, Gurley E, Bodhan P, Redford K, Gil G, Pandak W 
M (2004) Overexpression of cholesterol transporter StAR increases in vivo rates of 
bile acid synthesis in the rat and mouse  Hepatology 40: 910-917 
25. Hall E A, Ren S, Hylemon P B, Rodriguez-Agudo D, Redford K, Marques D, Kang D, 
Gil G, Pandak W M (2005) Detection of the steroidogenic acute regulatory protein, 
StAR, in human liver cells  BiochimBiophysActa 1733: 111-119 
26. Alpy F, Rousseau A, Schwab Y, Legueux F, Stoll I, Wendling C, Spiegelhalter C, 
Kessler P, Mathelin C, Rio M C, Levine T P, Tomasetto C (2013) STARD3 or 
STARD3NL and VAP form a novel molecular tether between late endosomes and the 
ER  J Cell Sci 126: 5500-5512 
27. van der Kant R, Zondervan I, Jansse L, Neefjes J (2013) Cholesterol-binding 
molecules MLN64 and ORP1L mark distinct late endosomes with transporters 
ABCA1 and NPC1  J Lipid Res 54: 2153-2165 
28. Rigotti A, Cohen D E, Zanlungo S (2010) STARTing to understand MLN64 function in 
cholesterol transport   J Lipid Res 51:2015-2017 
29. Charman M, Kennedy B E, Osborne N, Karten B (2010) MLN64 mediates egress of 
cholesterol from endosomes to mitochondria in the absence of functional Niemann-
Pick Type C1 protein  J Lipid Res 51: 1023-1034 
30. Borthwick F, Taylor J M, Bartholomew C, Graham A (2009) Differential regulation of 
the STARD1 subfamily of START lipid trafficking proteins in human macrophages  
FEBS Lett 583: 1147-1153 
31. Taylor J M W, Borthwick F, Bartholomew C, Graham A (2010) Overexpression of 
steroidogenic acute regulatory protein (StAR) increases macrophage cholesterol 
efflux to apolipoprotein AI  Cardiovasc Res 86: 526-534 
17 
 
32. Borthwick F, Allen A M, Taylor J M, Graham A (2010) Overexpression of STARD3 in 
human monocyte-macrophages induces an anti-atherogenic lipid phenotype   ClinSci 
(Lond) 119: 265-272 
33. Ianitti T, Graham A, Dolan S (2012) Increased central and peripheral inflammation 
and inflammatory hyperalgesia in Zucker rat model of leptin receptor deficiency and 
genetic obesity.  Exp Physiol 11: 1236-1245 
34. Bligh E G, Dyer W J (1959) A rapid method for total lipid extraction and purification  
Can J Biochem Physiol 37:911-917 
35. Tichauer J E, Morales M G, Amigo L, Galdames L, Klein A, Quinones V, Ferrada C, 
Alvarez A R, Rio M C, Miquel J F, Rigotti A, Zanlungo S (2007) Overexpression of 
the cholesterol-binding protein MLN64 induces liver damage in the mouse  World J 
Gastroenterol 13: 3071-3079 
36. Ha S D, Park S, Han C Y, Nguyen M L, Kim S O (2012) Cellular adaptation to 
anthrax lethal toxin-induced mitochondrial cholesterol enrichment, hyperpolarisation, 
and reactive oxygen species generation through downregulating MLN64 in 
macrophages.  Mol Cell Biol 32: 4846-4860. 
37. Tabas I (2002) Consequences of cellular cholesterol accumulation: basic concepts 
and physiological implications  J Clin Invest 100: 905-911 
38. Kishida T, Kostetskii I, Zhang Z, Martinez f, Liu P, Walkley S U, Dwyer N K, 
Blanchette-Mackie E J, Radice G L, Strauss J F III (2004) Targeted mutation of the 
MLN64 START domain causes only modest alterations in cellular sterol metabolism  
J Biol Chem 279: 19276-19285 
39. Zammit V A (2013) Hepatic triacylglycerol synthesis and secretion: DGAT2 as the 
link between glycaemia and triglyceridaemia Biochem J 451: 1-12. 
40. Puigserver P (2005) Tissue-specific regulation of metabolic pathways through the 
transcriptional coactivator PCG1-  Int J Obesity 29: 55-59 
41. Kovacs P, Hanson R L, Lee Y H, Kobes S, Permana P A, Bogardus C, Baier L J 
(2003) The role of insulin receptor substrate-1 gene (IRS1) in type 2 diabetes in Pima 
Indians  Diabetes 52: 3005-3009 
42. Li Y, Jadhav, L K, Zhang Y (2013) Bile acid receptors in non-alcoholic fatty liver 
disease  Biochem Pharmacol 86: 1517-1524 
43. Clore J N, Stillman J, Sugerman H (2000) Glucose-6-phosphatase flux in vitro is 
increased in type 2 diabetes Diabetes 49: 969-974 
44. Leung T-M, Nieto N (2013) CYP2E1 and oxidant stress in alcoholic and non-alcoholic 
fatty acid liver J Hepatol 58: 395-398 
18 
 
45. Kaur P, Reis M D, Couchman G R, Forjouh S N, Greene J F Jr, Asea A (2010) 
SERPINE links obesity and diabetes: a pilot study.  J Proteomics Bioinform 3: 191-
199. 
46. Yamaguchi K, Yang L, McCall S, Huang J, Yu X X, Pandey S K, Bhanot S, Monia B 
P, Li Y X, Diehl A M (2007) Inhibiting triglyceride synthesis improves hepatic 
steatosis but exacerbates liver damage and fibrosis in obese mice with non-alcoholic 
steatohepatitis.  Hepatology 45: 1366-1374 
47. Listenberger L L, Han X, Lewis S E, Cases S, Farese R V, Ory D S, Shaffer J E 
(2003) Triglyceride accumulation protects against fatty acid-induced lipotoxicity Proc 
Natl Acad Sci USA 100: 3077-3082 
48. Xiao, Q, Elovson J, Schumaker, V N (2000) Rat McA-RH7777 cells efficiently 
assemble rat apolipoprotein B-48 or larger fragments into VLDL but not human 
apolipoprotein B of any size. J. Lipid Res. 41: 16-25. 
49. Boren, J, Rustaeus, S, Olofsson, S O, (1994) Studies on the assembly of 
apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-
RH7777 cells. J. Biol. Chem. 269: 25879-88. 
50. Ota, T., Gayet, C, Ginsberg, H N (2008) Inhibition of apolipoprotein B100 secretion 
by lipid-induced hepatic endoplasmic reticulum stress in rodents. J. Clin. Invest. 118: 
316-32. 
51. Liang, J J, P. Oelkers, P, Guo, C, Chu, P C, Dixon, J L, Ginsberg, H N, Sturley, S L 
(2004) Overexpression of human diacylglycerol acyltransferase 1, acyl-
CoA:cholesterol acyltransferase 1, or acyl-CoA:cholesterol acyltransferase 2 
stimulates secretion of apolipoprotein B-containing lipoproteins in McA-RH7777 cells. 
J. Biol. Chem. 279: 44938-44. 
52. Hansson, P.K., Asztely, A-K, Clapham, J C, Schreyer, S A (2004) Glucose and fatty 
acid metabolism in McA-RH7777 hepatoma cells vs. rat primary hepatocytes: 
responsiveness to nutrient availability.  Biochim Biophys Acta 1684: 54-62 
53. Tran, K., Sun, F, Cui, Z, Thorne-Tjomsland, G, St Germain C, Lapierre, L R, McLeod, 
R S, Jamieson, J C, Yao, Z (2006) Attenuated secretion of very low density 
lipoproteins from McA-RH7777 cells treated with eicosapentaenoic acid is associated 
with impaired utilization of triacylglycerol synthesized via phospholipid remodeling. 










Serum and liver levels of cholesterol, triacylglycerol and choline-containing phospholipids 
from lean male (LM; n=10), obese male (OM n=6), lean female (LF; n=5) and obese female 
(OF; n=4) Zucker rats (1a).  Levels of StarD1 and StarD3 mRNA, relative to Gapdh, are in 
Figure 1b, and expression of StarD3 protein in Figure 1c; n=4.  *p<0.05, **p<0.01 compared 
with lean controls; §§ p<0.01 and §§§ p<0.001 for obese female compared with obese male 
animals. 
Figure 2 
Expression of CYP27A1 in wild type McArdle cells, relative to Gapdh, is shown in Figure 2a.  
Expression of StarD1 and StarD3 proteins, relative to Gapdh, in McArdle hepatoma cells, 
stably transfected with empty vector (EV; pCMV.Neo), or the same vector encoding each 
Gene of Interest (GOI) are shown in Figure 2b, with quantitation in three experiments shown 
in Figure 2d.  Transient knockdown of StarD3, relative to Gapdh, in wild type McArdle cells, 
by SiRNA (100nM; 48h), compared with siRNA control (100nM) is shown in Figure 2c, with 
quantitation in three experiments shown in Figure 2e. Lipidation of apoA-I (10g ml-1; 24h) 
with [3H]cholesterol by StarD1 and StarD3 overexpressing cell lines, compared with empty 
vector control, is shown in Figure 2e, and following StarD3 knockdown is shown in Figure 2f.  
**p<0.01 compared with EV; n=3.   
Figure 3 
Incorporations of 0.5mM [14C]acetate into cellular (3a) and secreted (3b) cholesterol ± 
0.35mM unlabelled (cold) oleate, from EV, StarD1 and StarD3 overexpressing hepatocytes; 
incorporations of this radiolabel into cellular (3c) and secreted (3d) cholesteryl esters, and 
incorporation of 0.7mM [14C]oleate ± 0.35mM unlabelled oleate, into cellular (3e) and 
secreted (3f) cholesteryl esters.  *p<0.05 and **p<0.01 compared with EV; n=3. 
Figure 4 
Incorporations of 0.25mM [3H]glycerol into cellular (4a) and secreted (4b) triacylglycerol ± 
0.35mM unlabelled (cold) oleate, from EV, StarD1 and StarD3 overexpressing hepatocytes; 
incorporations of 0.5mM [14C]acetate into the same pools, under the same conditions, are in 
Figures 4c and 4d; incorporations of 0.7mM [14C]oleate into cellular (4e) and secreted (4f) 
triacylglycerol.  *p<0.05 and ***p<0.001 compared with EV; n=3. 
Figure 5 
Expression of Dgat1, Dgat2 and Nr1h3, relative to Gapdh, in liver samples from lean and 
obese, male and female rats are shown in Figure 5a, 5b and 5e, respectively; n=4, **p<0.01, 
***p<0.001 compared with lean controls; §§ p<0.01 for obese female compared with obese 
male animals.  Levels of Dgat1, Dgat2 and Nr1h3 in EV, StarD1 and StarD3 overexpressing 
20 
 
hepatoma cells are shown in Figure 5c, 5d and 5f; **p<0.01, ***p<0.001 for gene expression 
differing from the EV control; n=4. 
Figure 6 
Effect of transient StarD3 knockdown (100nM SiRNA; 48h) on incorporation of 0.5mM 
[14C]acetate into cholesterol and cholesteryl ester pools, and incorporation of 0.7mM 
[14C]oleate into cholesteryl esters, for cellular (5a) and secreted (5b) lipids, respectively, 
compared with SiRNA control (100nM).  Incorporations of 0.25mM [3H]glycerol, 0.5mM 
[14C]acetate and 0.7mM [14C]oleate into cellular (5c) and secreted (5d) triacylglycerol, 
following StarD3 knockdown.  Nine independent transfections were performed; *p<0.05, 
**p<0.01 compared with SiRNA control. 
Figure 7 
Effect of overexpression of StarD3 (test)/EV(control) on expression of genes involved in 
insulin signalling (6a) cholesterol metabolism and transport (6b), carbohydrate and fat 
metabolism (6c) and inflammation and apoptosis (6d).  **p<0.01 and ***p<0.001 for genes 
exhibiting ≥2-fold up- or down-regulation; n.d.: ‘not detected’; n=3. 
 
 
 
